PRMT5 Inhibition Modulates E2F1 Methylation and Gene-Regulatory Networks Leading to Therapeutic Efficacy in JAK2

E2F1 Transcription Factor / metabolism Gene Regulatory Networks / genetics Humans Janus Kinase 2 / metabolism Methylation Mutation Protein-Arginine N-Methyltransferases / antagonists & inhibitors

Journal

Cancer discovery
ISSN: 2159-8290
Titre abrégé: Cancer Discov
Pays: United States
ID NLM: 101561693

Informations de publication

Date de publication:
11 2020
Historique:
received: 08 01 2020
revised: 26 05 2020
accepted: 10 07 2020
pubmed: 17 7 2020
medline: 15 12 2021
entrez: 17 7 2020
Statut: ppublish

Résumé

We investigated the role of PRMT5 in myeloproliferative neoplasm (MPN) pathogenesis and aimed to elucidate key PRMT5 targets contributing to MPN maintenance. PRMT5 is overexpressed in primary MPN cells, and PRMT5 inhibition potently reduced MPN cell proliferation

Identifiants

DOI: 10.1158/2159-8290.CD-20-0026 PMID: 32669286 PMC: PMC7642059
pubmed: 32669286
pii: 2159-8290.CD-20-0026
doi: 10.1158/2159-8290.CD-20-0026
pmc: PMC7642059
mid: NIHMS1613154
doi:

Substances chimiques

E2F1 Transcription Factor 0
E2F1 protein, human 0
PRMT5 protein, human EC 2.1.1.319
Protein-Arginine N-Methyltransferases EC 2.1.1.319
JAK2 protein, human EC 2.7.10.2
Janus Kinase 2 EC 2.7.10.2

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1742-1757

Subventions

Organisme : NCI NIH HHS
ID : P01 CA108671
Pays : United States
Organisme : NCI NIH HHS
ID : K99 CA248460
Pays : United States
Organisme : NCI NIH HHS
ID : K08 CA215317
Pays : United States
Organisme : NCI NIH HHS
ID : K08 CA188529
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : K08 CA218901
Pays : United States

Informations de copyright

©2020 American Association for Cancer Research.

Références

Cancer Cell. 2019 Aug 12;36(2):194-209.e9
pubmed: 31408619
Lancet. 2005 Mar 19-25;365(9464):1054-61
pubmed: 15781101
Nat Struct Mol Biol. 2019 Nov;26(11):999-1012
pubmed: 31611688
Mol Cell. 2017 Jan 5;65(1):8-24
pubmed: 28061334
J Hematol Oncol. 2017 Sep 29;10(1):156
pubmed: 28962635
Cell Mol Life Sci. 2015 Jun;72(11):2041-59
pubmed: 25662273
Trends Biochem Sci. 2011 Dec;36(12):633-41
pubmed: 21975038
Blood Cancer J. 2017 Dec 8;7(12):638
pubmed: 29217833
J Clin Invest. 2015 Sep;125(9):3532-44
pubmed: 26258414
Cancer Discov. 2015 Mar;5(3):316-31
pubmed: 25572172
Nat Rev Cancer. 2013 Jan;13(1):37-50
pubmed: 23235912
N Engl J Med. 2009 May 28;360(22):2289-301
pubmed: 19474426
Nat Genet. 2010 Aug;42(8):722-6
pubmed: 20601953
N Engl J Med. 2005 Apr 28;352(17):1779-90
pubmed: 15858187
Cell Rep. 2015 Dec 22;13(11):2345-2352
pubmed: 26686625
Nature. 2005 Apr 28;434(7037):1144-8
pubmed: 15793561
EMBO J. 2012 Apr 4;31(7):1785-97
pubmed: 22327218
N Engl J Med. 2012 Mar 1;366(9):787-98
pubmed: 22375970
Trends Biochem Sci. 2004 Aug;29(8):409-17
pubmed: 15362224
Leukemia. 2016 Aug;30(8):1701-7
pubmed: 27211272
J Clin Oncol. 2011 Apr 1;29(10):1356-63
pubmed: 21300928
Blood. 2014 May 29;123(22):e123-33
pubmed: 24740812
Blood. 2017 Mar 23;129(12):1607-1616
pubmed: 28159736
Biochim Biophys Acta. 2014 Aug;1839(8):702-10
pubmed: 24583552
Sci Signal. 2016 Aug 30;9(443):rs9
pubmed: 27577262
Cancer Cell. 2011 Feb 15;19(2):283-94
pubmed: 21316606
Blood. 2005 Nov 15;106(10):3377-9
pubmed: 16081687
J Exp Med. 2017 Jul 3;214(7):1901-1912
pubmed: 28550162
Mol Cell. 2009 Jan 16;33(1):1-13
pubmed: 19150423
Nature. 2012 Sep 6;489(7414):155-9
pubmed: 22820254
N Engl J Med. 2012 Mar 1;366(9):799-807
pubmed: 22375971
Blood. 2011 Dec 8;118(24):6392-8
pubmed: 21860020
Cell Rep. 2016 Apr 19;15(3):574-587
pubmed: 27068473
Exp Hematol. 2016 Jun;44(6):435-41
pubmed: 27026282
Blood Cancer J. 2016 Jun 24;6(6):e439
pubmed: 27341078
Science. 2016 Mar 11;351(6278):1214-8
pubmed: 26912360
Blood. 2017 Dec 28;130(26):2848-2859
pubmed: 29042365
Genes Dev. 2010 Dec 15;24(24):2772-7
pubmed: 21159818
Biomed Pharmacother. 2019 Jun;114:108790
pubmed: 30903920
Blood. 2010 Apr 8;115(14):2919-27
pubmed: 20154217
DNA Repair (Amst). 2013 Jul;12(7):459-65
pubmed: 23684798
ACS Med Chem Lett. 2018 Apr 23;9(7):612-617
pubmed: 30034588
Cytokine Growth Factor Rev. 2013 Apr;24(2):133-45
pubmed: 23415024
J Exp Med. 2012 Jan 16;209(1):35-50
pubmed: 22231305
Cancer Cell. 2015 Jul 13;28(1):15-28
pubmed: 26175413
Cancer Cell. 2010 Jun 15;17(6):584-96
pubmed: 20541703
Br J Haematol. 2009 Jun;145(6):788-800
pubmed: 19388938

Auteurs

Friederike Pastore (F)

Molecular Cancer Medicine Service, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Center for Epigenetics Research, Memorial Sloan Kettering Cancer Center, New York, New York.

Neha Bhagwat (N)

Prelude Therapeutics Inc., Wilmington, Delaware.

Alessandro Pastore (A)

Molecular Cancer Medicine Service, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.

Aliaksandra Radzisheuskaya (A)

Center for Epigenetics Research, Memorial Sloan Kettering Cancer Center, New York, New York.
Cell Biology Program, Memorial Sloan Kettering CancerCenter, New York, New York.

Abdul Karzai (A)

Molecular Cancer Medicine Service, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Center for Epigenetics Research, Memorial Sloan Kettering Cancer Center, New York, New York.

Aishwarya Krishnan (A)

Molecular Cancer Medicine Service, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Center for Epigenetics Research, Memorial Sloan Kettering Cancer Center, New York, New York.

Bing Li (B)

Molecular Cancer Medicine Service, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Center for Epigenetics Research, Memorial Sloan Kettering Cancer Center, New York, New York.

Robert L Bowman (RL)

Molecular Cancer Medicine Service, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Center for Epigenetics Research, Memorial Sloan Kettering Cancer Center, New York, New York.

Wenbin Xiao (W)

Molecular Cancer Medicine Service, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Center for Epigenetics Research, Memorial Sloan Kettering Cancer Center, New York, New York.
Hematopathology Service, Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
ORCID: 0000-0001-8586-8500

Aaron D Viny (AD)

Molecular Cancer Medicine Service, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Center for Epigenetics Research, Memorial Sloan Kettering Cancer Center, New York, New York.

Anouar Zouak (A)

Molecular Cancer Medicine Service, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Center for Epigenetics Research, Memorial Sloan Kettering Cancer Center, New York, New York.

Young C Park (YC)

Molecular Cancer Medicine Service, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Center for Epigenetics Research, Memorial Sloan Kettering Cancer Center, New York, New York.

Keith B Cordner (KB)

Molecular Cancer Medicine Service, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Center for Epigenetics Research, Memorial Sloan Kettering Cancer Center, New York, New York.

Stephanie Braunstein (S)

Molecular Cancer Medicine Service, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Center for Epigenetics Research, Memorial Sloan Kettering Cancer Center, New York, New York.

Jesper L Maag (JL)

Center for Epigenetics Research, Memorial Sloan Kettering Cancer Center, New York, New York.
ORCID: 0000-0002-2578-8872

Alexander Grego (A)

Prelude Therapeutics Inc., Wilmington, Delaware.

Jaanvi Mehta (J)

Prelude Therapeutics Inc., Wilmington, Delaware.

Min Wang (M)

Prelude Therapeutics Inc., Wilmington, Delaware.

Hong Lin (H)

Prelude Therapeutics Inc., Wilmington, Delaware.

Benjamin H Durham (BH)

Molecular Cancer Medicine Service, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.

Richard P Koche (RP)

Center for Epigenetics Research, Memorial Sloan Kettering Cancer Center, New York, New York.

Raajit K Rampal (RK)

Molecular Cancer Medicine Service, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
ORCID: 0000-0002-0355-6368

Kristian Helin (K)

Center for Epigenetics Research, Memorial Sloan Kettering Cancer Center, New York, New York.
Cell Biology Program, Memorial Sloan Kettering CancerCenter, New York, New York.
Biotech Research and Innovation Centre (BRIC), University of Copenhagen, Copenhagen, Denmark.
The Novo Nordisk Foundation of Stem Cell Research (Danstem), University of Copenhagen, Copenhagen, Denmark.
ORCID: 0000-0003-1975-6097

Peggy Scherle (P)

Prelude Therapeutics Inc., Wilmington, Delaware.

Kris Vaddi (K)

Prelude Therapeutics Inc., Wilmington, Delaware.

Ross L Levine (RL)

Molecular Cancer Medicine Service, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York. leviner@mskcc.org.
Center for Epigenetics Research, Memorial Sloan Kettering Cancer Center, New York, New York.
Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Center for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, New York.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Facteurs de transcription › Facteurs de transcription E2F › Facteur de transcription E2F1 › PRMT5 Inhibition Modulates E2F1 Methylation...
questionsmedicales.fr › Phénomènes génétiques › Structures génétiques › Séquences d'acides nucléiques régulatrices › Réseaux de régulation génique › PRMT5 Inhibition Modulates E2F1 Methylation...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › PRMT5 Inhibition Modulates E2F1 Methylation...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines tumorales › Protéines oncogènes › Protéines proto-oncogènes › Kinase Janus-2 › PRMT5 Inhibition Modulates E2F1 Methylation...
questionsmedicales.fr › Métabolisme › Alkylation › Méthylation › PRMT5 Inhibition Modulates E2F1 Methylation...
questionsmedicales.fr › Phénomènes génétiques › Variation génétique › Mutation › PRMT5 Inhibition Modulates E2F1 Methylation...
questionsmedicales.fr › Enzymes et coenzymes › Enzymes › Transferases › One-carbon group transferases › Methyltransferases › Protein Methyltransferases › Protein-arginine N-methyltransferases › PRMT5 Inhibition Modulates E2F1 Methylation...